Tirilazad mesylate increases dopaminergic neuronal survival in the in Oculo grafting model.
Grafting of fetal ventral mesencephalon in Parkinson's disease has been extensively studied. A crucial draw back of this technique is the low survival rate of the dopaminergic neurons. It has been documented that only 5-20% of the grafted neurons survive, and to enhance graft efficacy to a satisfying level, increased cell survival is of utmost desire. In this study we have used the antioxidant tiriliazad mesylate (U-74006F) to study the effect on the survival of dopaminergic neurons after grafting. The in oculo grafting model was used and ventral mesencephalon was dissected from E14-E15 rat fetuses in Hanks' balanced salt solution (HBSS), in Dulbecco's modified Eagle medium (DMEM), or in 0.3, 3.0, or 30 microM U-74006F diluted in DMEM. The tissue was then inserted into the anterior chamber of the eye. Some of the transplants were further treated with intraocular injections of 3 or 30 microM U-74006F (5 microliters) weekly for 2 weeks. Quantification of tyrosine hydroxylase (TH)-immunoreactive profiles revealed that in transplants treated with U-74006F at dissection only, no change in the number of TH-positive neurons was found. Pretreatment of 0.3 microM U-74006F during dissection combined with intraocular injections of U-74006F after grafting, on the other hand, resulted in a dose-dependent enhancement of survival of TH-positive neurons. Dissection in, and intraocular treatment with, 3 microM U-74006F resulted in a significantly enhanced survival of TH-positive neurons whereas using U-74006F at a concentration of 30 microM did not change the cell survival compared to solely DMEM-treated grafts. Thus, 30 microM was interpreted to be an overdose. Comparing cell survival when dissected in DMEM with that dissected in HBSS showed that DMEM was clearly superior. Nerve fiber formation was most pronounced in grafts treated with 3 microM U-74006F. In conclusion, survival of TH-positive neurons is enhanced by U-74006F, which is readily available for clinical use and thus could be employed to enhance graft survival when transplanting patients suffering from Parkinson's disease.
Björklund
L
L
Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
Spenger
C
C
Strömberg
I
I
D000818:Animals; D000867:Anterior Chamber; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D016380:Brain Tissue Transplantation; D004298:Dopamine / Q000032:analysis*; D004305:Dose-Response Relationship, Drug; D016332:Fetal Tissue Transplantation; D006085:Graft Survival / Q000187:drug effects*; D008636:Mesencephalon / Q000166:cytology* / Q000196:embryology; D009412:Nerve Fibers / Q000648:ultrastructure; D009474:Neurons / Q000737:chemistry / Q000187:drug effects* / Q000637:transplantation; D010300:Parkinson Disease / Q000601:surgery; D011281:Pregnatrienes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D016042:Transplantation, Heterotopic
D000975:Antioxidants; D011281:Pregnatrienes; D004298:Dopamine; C053355:tirilazad